Abstract | BACKGROUND: PATIENTS AND METHODS: Seventy-one postmenopausal patients were randomized to receive an i.m. injection of depot MPA 500 mg on days 1, 14 and 28, or oral megestrol acetate 40 mg daily for 6 weeks. Patients recorded daily the number and severity of their hot flashes; response was defined as a > or =50% decrease in the number and severity of hot flashes. RESULTS: At week 6, hot flashes were reduced by 86% on average in the whole group of patients, without significant differences between the two progestins. Response was obtained by 75 and 67% of patients receiving MPA or megestrol, respectively (P = 0.5). Responders were followed to assess maintenance of response (without further treatment), which was significantly better with i.m. MPA: in this group, 89% of responders still showed a benefit at week 24, compared with 45% in the megestrol group (P = 0.03). CONCLUSIONS:
|
Authors | G Bertelli, M Venturini, L Del Mastro, M Bergaglio, P Sismondi, N Biglia, S Venturini, G Porcile, P Pronzato, M Costantini, R Rosso |
Journal | Annals of oncology : official journal of the European Society for Medical Oncology
(Ann Oncol)
Vol. 13
Issue 6
Pg. 883-8
(Jun 2002)
ISSN: 0923-7534 [Print] England |
PMID | 12123333
(Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Medroxyprogesterone Acetate
- Megestrol Acetate
|
Topics |
- Administration, Oral
- Aged
- Breast Neoplasms
(complications, diagnosis, drug therapy)
- Chi-Square Distribution
- Dose-Response Relationship, Drug
- Drug Administration Schedule
- Female
- Follow-Up Studies
- Hot Flashes
(complications, diagnosis, drug therapy)
- Humans
- Injections, Intramuscular
- Medroxyprogesterone Acetate
(administration & dosage)
- Megestrol Acetate
(administration & dosage)
- Middle Aged
- Patient Satisfaction
- Postmenopause
- Probability
- Reference Values
- Severity of Illness Index
- Treatment Outcome
|